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ABSTRACT
Targeting the PD-1/PD-L1 immunologic checkpoint with monoclonal antibodies 
has provided unprecedented results in cancer treatment in the recent years. 
Development of chemical inhibitors for this pathway lags the antibody development 
because of insufficient structural information. The first nonpeptidic chemical inhibitors 
that target the PD-1/PD-L1 interaction have only been recently disclosed by Bristol-
Myers Squibb. Here, we show that these small-molecule compounds bind directly to 
PD-L1 and that they potently block PD-1 binding. Structural studies reveal a dimeric 
protein complex with a single small molecule which stabilizes the dimer thus occluding 
the PD-1 interaction surface of PD-L1s. The small-molecule interaction “hot spots” on 
PD-L1 surfaces suggest approaches for the PD-1/PD-L1 antagonist drug discovery.
INTRODUCTION
Cancer cells avoid immune surveillance by 
overexpressing negative immunologic regulators. In 
normal conditions these regulators provide checkpoints 
that restrain the immune system against targeting self-
antigens. However, when overproduced by cancer cells, 
they protect those cells against hosts’ immune system. 
Even more, such interactions result in the exhaustion (loss 
of function) of the antigen-specific effector T-cells. The 
immunosuppressive environment created in these ways 
permits the cancer cells to proliferate unrestrained. The 
reversal of these effects by blocking the interaction of the 
negative immunologic regulators on cancer cells, or by 
blocking their receptors on immune effector cells, should 
in principle help to eliminate cancer [recent reviews: 
1-5]. Indeed, the proof-of-concept was established 
with the hope-rising results of clinical trials evaluating 
ipilimumab, an antibody blocking the immune checkpoint 
receptor CTLA-4, resulting in the FDA acceptance for 
the combined anti-cancer treatment in 2011 [3]. Even 
more encouraging results were more recently obtained 
for nivolumab and pembrolizumab, antibodies targeting 
the programmed death 1 (PD-1)/PD-1 ligand (PD-L1) 
immune checkpoint. The tumor responses in clinical 
trials in melanoma were impressive enough to merit 
the accelerated approval of these antibodies in 2014 
[2] [6-7] [http://www.fda.gov/NewsEvents/ Newsroom/
PressAnnouncements/ucm436534.htm]. Moreover, in 
2015, after demonstrating unprecedented results in clinical 
trial in the metastatic squamous NSCLC, nivolumab has 
gained FDA acceptance in this indication, becoming the 
first monotherapy in more than 15 years to demonstrate 
proven superior overall survival compared to the standard 
of care [http://www.fda.gov/Drugs/InformationOnDrugs/
ApprovedDrugs/ucm436566.htm]. Numerous further 
clinical trials are currently in progress [8].
Inhibition of the PD-1/PD-L1 axis is also feasible 
by targeting PD-L1. Objective responses were observed 
in melanoma, NSCLC and certain other solid tumors in 
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the phase I clinical trial evaluating monoclonal antibody 
BMS-936559 (MDX1105) [9]. Similar encouraging 
results were obtained with MEDI4736 antibody in 
NSCLC patients [10]. The third anti-PD-L1 antibody 
currently evaluated in clinics, MPDL3280A, demonstrated 
positive results in melanoma, NSCLC and genitourinary 
cancers [11]. It was also granted an FDA breakthrough 
designation for the metastatic urothelial bladder cancer 
after demonstrating impressive results in the phase I trial 
in which tumor shrinkage was observed in 43% of patients 
[12]. Additional phase I and phase II trials of anti-PD-L1 
antibodies are currently in progress [8].
Ongoing trials evaluating the PD-1 and PD-L1 
targeting antibodies in multiple indications in cancer 
portend further rapid development. Moreover, initial 
results demonstrate association between PD-L1 status and 
the response to the treatment [13]. A reliable biomarker 
would likely result in further improvement in observed 
response rates by rational patient selection. Overall, it is 
currently expected that antibodies targeting immunologic 
regulators will soon become a significant aspect of the 
therapy within a variety of malignancies [8].
This impressive clinical development of the 
antibodies that interfere with the PD-1/PD-L1 axis 
is in contrast to the development of small-molecule 
modulators for this interaction. Several low-molecular 
weight immunomodulators targeting the PD-1/PD-
L1 signaling pathway were reported. These are based 
on peptidomimetics [14-15] and macrocyclic peptides 
[16]. More recently, in 2015, the 1,2,4-oxadiazole- and 
1,2,4-thiadiazole-based inhibitors that contain an extensive 
peptidic component have been proposed to suppress and/
or inhibit the PD-1/PD-L1 signaling pathway, although no 
data supporting that action has been provided [17]. We 
have tested several of the described peptidomimetic agents 
and could show no direct binding to the target PD proteins, 
suggesting that possibly other targets are involved. Bristol-
Myers Squibb has recently disclosed the first entirely 
nonpeptidic molecules which are claimed to be “useful as 
inhibitors of the PD-1/PD-L1 protein/protein interaction”, 
although no detailed information was provided [18]. 
Clearly, progress of small molecule modulators of 
PD-1/PD-L1 pathway is lagging behind that of antibodies, 
which is partially related to insufficient structural 
information to guide rational design and development. 
The structure of the complex of the murine PD-1 and 
human PD-L1 revealed the overall binding mode for the 
PD-1/PD-L1 interaction [19], but relatively low sequence 
identity of human and murine orthologues limited the 
relevance of this finding for drug design. The structures of 
human PD-1 (PDB 3RRQ) and human PD-L1 (PDB 3BIS, 
3FN3, 4Z18, 5C3T) have been determined, but those in 
turn did not account for significant plasticity within the 
human PD-1 upon complex formation demonstrated only 
very recently by our structure of the fully human PD-1/
PD-L1 complex [20]. Although the above structures 
provided a complete description of the interaction, the flat 
surface of the protein-protein interface still complicates 
drug design efforts in the absence of structural information 
on the small-molecule inhibitors in complex with either 
PD-1 or PD-L1 to guide further rational drug development.
Herein, we report characterization of the interaction 
of Bristol-Myers Squibb (BMS) compounds with the target 
protein. We show that they act by directly binding to PD-
L1 and not PD-1 and effectively dissociate a preformed 
PD-1/PD-L1 complex in vitro. We further show that they 
inhibit the PD-1/PD-L1 interaction by inducing PD-L1 
dimerization through PD-1 interacting surface. We provide 
the first crystal structures of a small-molecule inhibitors 
bound to its target PD protein, in this case the PD-L1 
dimer. Together with our biochemical data, the provided 
insight into this protein-inhibitor interaction and detailed 
definition of the binding site “hot spots” should facilitate 
more dynamic progress in the development of the PD-1/
PD-L1 immune checkpoint modulators.
RESULTS
BMS-8 and BMS-202 bind to PD-L1 and 
dissociate the human PD-1/PD-L1 complex in 
NMR assays 
The small-molecule PD-1/PD-L1 inhibitors of 
Bristol-Myers Squibb are based on the (2-methyl-
3-biphenylyl)methanol scaffold [18]. In the original 
disclosure, the inhibition of the formation of PD-L1/
PD-1 protein/protein complex was demonstrated in a 
homogenous time-resolved fluorescence (HTRF) assay, 
but mechanistic or structural features, including the actual 
target protein, were not disclosed. We have synthesized 
and tested four examples of their compounds with the 
reported inhibition IC50 towards the PD-L1/PD-1 complex 
in the range of 18 to 200 nM, the lowest IC50 values in the 
series of about 200 compounds. The compounds that we 
have studied are 8, 37, 202 and 242 in the patent, and these 
are designated herein as BMS-8, BMS-37, BMS-202 and 
BMS-242, respectively (Figure 1). 
To unambiguously validate if these compounds bind 
to PD-1 or PD-L1, we used NMR, a method that monitors 
the direct binding of a small molecule to its target 
protein [21-22]. We performed binary titrations, using 
the “SAR-by-NMR” approach [21]. The method relies 
on monitoring chemical shift perturbations in 2D 1H-15N 
HMQC spectra of 15N-labeled proteins upon interaction 
with tested ligands. The 15N labeled PD-L1 was titrated 
with increasing amount of tested compound while the 
1H-15N signals were monitored using 2D HMQC NMR 
experiment. Significant shifts in the correlation NMR 
signals of PD-L1 upon addition of each tested compound 
documented their direct binding to PD-L1 (Figure S1 and 
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S2). No significant shifts were observed upon titration 
of the 15N labeled PD-1 with the tested compounds, 
demonstrating their specificity for binding to PD-L1 (data 
not shown).
The capability of BMS-202 to block the PD-1/PD-
L1 interaction was evaluated in the NMR based AIDA 
assay. The assay monitors broadening of resonance 
signals upon protein-protein complex formation related to 
increased relaxation time of the higher molecular weight 
entities [23-25]. To this end the 15N labeled PD-1 was 
first titrated with the non-labeled PD-L1 until no further 
changes in the linewidth of the 1H-15N resonance peaks 
was observed as monitored by HMQC (Figure S3). In such 
conditions the sample contained slight excess of PD-L1 
over PD-1. The molecules formed a tight complex which 
molecular weight was estimated at around 30 kDa based 
on the relaxation time analysis. This corresponds well 
with the calculated mass of a 1:1 complex (27.5 kDa). 
Upon titration of this preformed complex with BMS-202 
narrowing of 1H-15N signals was observed which provides 
direct evidence of the complex dissociation. 
BMS-8 and BMS-202 selectively induce thermal 
stabilization of PD-L1 
To facilitate the choice of the compound suitable 
for structural studies, we evaluated the relative affinity 
of BMS-8 and BMS-202 towards PD-L1 and PD-L2 
using differential scanning fluorimetry (DSF) [26]. 
DSF monitors thermal unfolding of the protein in the 
presence of a fluorescent dye sensitive to the changes in 
hydrophobicity (protein denaturation). Binding of small-
molecule ligands induces thermal stabilization of the target 
protein which is proportional to compound affinity [27]. 
PD-L1 exhibited a relatively low melting temperature (Tm) 
of 35.4oC (Figure S4A). BMS-8 stabilized the thermally 
induced unfolding of PD-L1 by 9.4oC (Tm=44.8
oC), 
whereas BMS-202 by 13oC (Tm=48.4
oC). PD-L2 was 
characterized by a comparable melting temperature as 
PD-L1 (38.2oC), however, neither BMS-8 nor BMS-202 
significantly affected the Tm value (38.6
oC and 35.6oC, 
for BMS-8 and BMS-202, respectively) (Figure S4B). 
These results further confirm the interaction of both tested 
compounds with hPD-L1 and indicate that BMS-8 exhibits 
lower affinity compared to BMS-202. Furthermore, 
the presented data suggests that both compounds bind 
specifically only to PD-L1, but not PD-L2. 
Structural basis of the interaction of BMS-202 
with PD-L1 
Having confirmed the affinity of BMS-202 
towards PD-L1 and its ability to dissociate the PD-1/
PD-L1 interaction, we crystallized the compound in the 
Figure 1: Chemical structures of the BMS-8, -37, -202 and -242 inhibitors of PD-1/PD-L1 interaction. Compound 
numbering according to patent application WO2015034820 (A1).
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complex with the target protein. The obtained crystals 
diffracted to the 2.2 Å resolution (Table 1). Four protein 
molecules found in the asymmetric unit are organized 
into two dimers with one inhibitor molecule located at 
the interface of each dimer (i.e. the stoichiometry of the 
BMS-202 : PD-L1 in the complex is 1: 2, respectively) 
(Figure 2A). No additional inhibitor molecules were found 
within the structure. The protein dimer exhibits a pseudo 
2-fold rotational symmetry around an axis parallel to the 
long axis of the PD-L1 molecule. The inhibitor is located 
roughly perpendicular to the dimer pseudo-symmetry 
axis and its disposition does not follow the symmetry 
of the dimer (Figure 2A). Both the binding site of the 
inhibitor and the intermolecular interactions within the 
dimer involve the PD-1 interaction surface of PD-L1, 
providing a rationale of the mechanism of action of BMS-
202 (ie. dimerization related occlusion of PD-1 interaction 
surface).
Both inhibitor molecules are well defined by the 
electron density allowing unambiguous positioning of 
all moieties (Figure S5). The inhibitor inserts deep into a 
cylindrical, hydrophobic pocket created at the interface of 
two monomers within the dimer (Figure 3 and Figure S6). 
The pocket is open to the solvent on one side of the dimer 
Table 1: Data collection and refinement statistics (molecular replacement)
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and restricted by the sidechain of 
A
Tyr56 on the opposite 
side (the protein molecules are annotated by subscripts 
A, B, C and D according to the chain arrangement in the 
crystal structure; the inhibitor disposition is described here 
based on AB dimer and is similar in CD dimer unless noted 
otherwise). The 2-methylbiphenyl core of the inhibitor 
anchors at the very bottom of the pocket (Figure 2B and 
Figure S7). The distal phenyl ring within the biphenyl 
creates a T-stacking interaction with the sidechain of 
A
Tyr56 and is further stabilized by π-alkyl interactions with 
the sidechains of 
A
Met115 and BAla121. The orientation of 
central methyl-phenyl ring is roughly related to that of the 
distal ring by a pseudo glide plane through ring connecting 
bond and roughly 45° to the ring planes. The major 
interactions of the central ring involve the hydrophobic 
interactions with 
A
Ala121 and BMet115. The methyl of this 







Tyr123 (Figure 2B and Figure 
S7). Moreover the methyl group serves to turn the two 
phenyl groups out of coplanarity to preorganize the ligand 
binding conformation. The methoxy-pyridine moiety 
provides a significant contribution to the compound 
binding including π-π stacking with the ring of BTyr56 
and a number of polar interactions with the A monomer 
including the carbonyl-π interaction with the backbone 
of 
A
Ala121, the anion-π interaction with the sidechain of 
A
Asp122, a water-mediated lone-pair-π interaction with the 
backbone of 
A
Phe19 and the water-mediated interactions 





Lys124 and the backbone carbonyl of 
A
Tyr123. 
The extended N-(2-aminoethyl)acetamide moiety of the 
inhibitor provides additional electrostatic interactions, but 
only with the A monomer (and corresponding C monomer 
for the second inhibitor molecule contained in the 
asymmetric unit). A water-mediated interaction with the 
backbone carbonyl of 
A
Phe19 is observed for both inhibitor 
molecules contained in the asymmetric unit, but further 
interactions of the distal parts of the acetamide group 
Figure 2: Crystal structure of BMS-202/PD-L1 complex. A. Within the asymmetric unit four molecules of PD-L1 (mixed ribbon/
surface representation) are organized into two dimers (green and blue, and orange and brown). Each dimer binds a single molecule of BMS-
202 (yellow) at the dimer interface. B. Detailed interactions of BMS-202 at the binding cleft of PD-L1 dimer (stereoview). BMS-202 binds 
at a hydrophobic cavity formed upon PD-L1 dimerization. Color coding as in panel a. Water molecules are represented by grey spheres. 
Hydrogen bonds are shown as black dotted lines.
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differ between the monomers. This is unrelated to crystal 
packing since no symmetry related molecules locate near 
the described moiety, but rather seems an effect of its 
flexibility (evidenced by high temperature factors, Figure 
S8C) and a solvent-exposed character of the binding site 
in this region (the described inhibitor moiety interacts 
with surface residues rather than within a defined pocket; 
Figure 2B, Figure 3). In one of the dimers (AB) contained 
in the asymmetric unit the acetamide moiety contributes 
a hydrogen bond to the sidechain of 
A
Lys124 whereas in 
the second dimer (CD) with that of CThr20. Overall, the 
inhibitor-protein interaction is best described as bimodal, 
spatially divided into hydrophobic and electrostatic parts 
following the inhibitor bimodal design.
Crystal structure of PD-L1/BMS-8 complex 
supports compound induced dimerization of PD-
L1
The crystal structure of PD-L1/BMS-202 complex 
suggests that BMS-202 induces dimerization of PD-L1. 
To assess if the observed dimerization is induced by 
crystallization conditions or rather is specific for this class 
of compounds we crystallized BMS-8 in complex with 
PD-L1 (Table 1). The crystal structure was solved at 2.3 
Å resolution and clear and continuous electron density 
allowed unambiguous positioning of the inhibitor and all 
the interacting residues. The asymmetric unit contains 
two molecules of PD-L1 organized in a dimer identical 
to that observed in the structure of PD-L1/BMS-202. A 
single molecule of BMS-8 binds at the interface of the 
dimer in a pocket almost identical to that found in PD-
L1/BMS-202 complex (Figure S8B). The disposition of 
the buried part of BMS-8 is identical to that observed for 
BMS-202 and the only differences are observed in the part 
directed towards the solvent (Figure S8A). Overall, the 
binding mode of the compound and geometry of PD-L1 
dimer are identical in the structures containing BMS-8 
and BMS-202 save for detailed interactions of the solvent 
directed moieties. The fact that crystals of PD-L1/BMS-8 
complex were obtained in different conditions and belong 
to a different space group than those of PD-L1/BMS-202 
strongly advocates that PD-L1 dimerization reflects a 
specific mechanism of action of BMS compounds rather 
than a crystallization artifact.
BMS-202 and BMS-8 induce dimerization of PD-
L1 in solution 
To further assess if BMS compounds induced 
dimerization of PD-L1 is an effect of tight packing within 
the crystal or rather constitutes the actual mechanism of 
Figure 3: BMS-202 binds inside a cylindrical cleft at PD-L1 dimer interface. Hydrophobic pocket accommodating the inhibitor 
and formed at PD-L1 dimer interface is shown from the solvent accessible side (stereoview). N-(2-aminoethyl)acetamide moiety of the 
inhibitor is visible. The PD-L1 molecules forming the dimer are colored blue and green for chain A and B, respectively.
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action, we checked whether BMS-202 and BMS-8 induce 
the PD-L1 dimerization in solution. To this end PD-L1 
was characterized by size exclusion chromatography 
in the presence and absence of tested compounds. Apo-
PD-L1 yielded a single peak corresponding to a protein 
of molecular weight of 17 kDa, suggesting a monomeric 
state of the apoprotein in solution. In the presence of 
each compound the peak shifted to shorter retention time 
corresponding to a protein of around 34 kDa, consistent 
with a calculated molecular weight of a dimer (Figure S9). 
This indicates the PD-L1 dimerization by both BMS-202 
and BMS-8 in solution.
To further evaluate the presumed BMS compound 
induced PD-L1 dimerization in solution, we titrated PD-
L1 with BMS-202, BMS-8, BMS-37 and BMS-242 while 
monitoring the 1H resonance linewidth by NMR. In all 
the cases, the well resolved narrow resonance peaks in 
the aliphatic region of 1H NMR spectrum of apo-PD-L1 
exhibited significant broadening upon addition of each 
compound indicating significant increase in the molecular 
weight of the complex (Figure S1B and S2). The molecular 
weight of each complex estimated from relaxation time 
analysis was around 30 kDa, which can only be explained 
by the compound induced PD-L1 dimerization. Similar 
resonance linewidth broadening was observed in the 
1H-15N HMQC spectra when the 15N-labeled PD-L1 was 
titrated with BMS-202 (Figure S1A).
Overall, the NMR titration experiments support 
the results obtained in gel filtration indicating that all 
tested BMS compounds induce dimerization of PD-L1 in 
solution and that such preformed dimeric state is reflected 
by the crystal structures provided in this study.
Multiple hydrophobic and electrostatic interactions 
stabilize the homodimer (Figure 2B and Figure S8B). 
The interactions are discussed based on PD-L1/
BMS-202 structure, but are similar in PD-L1/BMS-
8 structure. The hydroxyl group of 
A
Tyr56 creates a 2.6 
Å-long hydrogen bond and hydrophobic contacts with 
Figure 4: Rationale for inhibition of PD-1/PD-L1 complex formation by BMS-202. (A) BMS-202 induced PD-L1 dimer and 
PD-1/PD-L1 complex were superimposed such that a single molecule of PD-L1 (model A) within the BMS-202 (yellow) induced dimer 
(blue ribbon- model A, green surface – model B) was superposed with PD-L1 molecule (not shown) within PD-1/PD-L1 complex (PD-1 
shown as red ribbon). Model B within PD-L1 dimer and PD-1 do not overlay perfectly (are shifted by around 10Å), but BMS-202 induced 
dimerization of PD-L1 masks almost the entire PD-1 interaction surface thereby preventing PD-1/PD-L1 interaction. Same is true for 
BMS-8 containing structure (not shown) (B) Superposition of the PD-L1 molecules extracted from apo-PD-L1 (orange ribbon; PDB 5C3T), 
PD-1/PD-L1 (PDB 4ZQK; PD-L1 shown as grey ribbon; PD-1 is not shown) and PD-L1/BMS-202 complex (model A shown as blue 
ribbon; BMS-202 shown as yellow sticks) structures demonstrates that PD-L1 does not undergo significant backbone rearrangement upon 
interaction with BMS-202. Model B of PD-L1/BMS-202 dimer is shown as green ribbon and surface. Same is true for BMS-8 containing 
structure (not shown).
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BAsp122 (graphical representation of the interactions is 
presented in Figure S10 [28]). BAla121 creates a net of 





at the same time interacts with BGly120 also utilizing 
hydrophobic interactions. Ser117 in the 
A
PD-L1 and 
BPD-L1 molecules participate in the 2.9 Å hydrogen bond 
and in the hydrophobic contacts, as the Ser117 residues 
are located parallel to each other. Next, 
A
Tyr123 joins with 
both BMet115 and BGlu58 using hydrophobic contacts 
and hydrogen bonds between the carboxyl of BGlu58 and 
hydroxyl of tyrosine. 
A
Arg113 builds a dense interaction 
network consisting of a salt bridge, hydrogen bonding 
and hydrophobic interactions with BGlu58 and BAsp61 
and hydrophobic contacts with BGlu60 and BArg113 as 
well. BArg113 residue also contributes a salt bridge and 
hydrogen bonding with 
A
Asp61 which creates next salt 
bridge with BArg125. BTyr123 interacts with AGlu58 and 
A
Met115 through hydrophobic contacts and hydrogen 
bonds.
DISCUSSION
Monoclonal antibodies targeting immunologic 
checkpoints and especially the PD-1/PD-L1 axis provided 
spectacular results in cancer therapy in the recent years 
[recent reviews: 1-4]. Given the large number of ongoing 
clinical trials this success will likely expand in the near 
future. Development of small molecule inhibitors of 
PD-1/PD-L1 checkpoint is currently much behind that 
of the antibodies, but first tool compounds have already 
been disclosed. The number of announced commercial 
programs within this novel segment of immunomodulatory 
molecules and the detailed structural insight provided 
within this study promise dynamic progress in the field in 
the near future. 
Several low-molecular weight immunomodulators 
targeting the PD-1/PD-L1 pathway that are based on 
peptidomimetics [14-15] and macrocyclic peptides [16] 
were reported. We have tested several of the described 
peptidomimetics. The results obtained by us did not 
indicate binding to either of the PD proteins suggesting 
that these compounds modulate the PD-1/PD-L1 pathway 
only indirectly (data not shown). 
The first group of true small-molecule inhibitors 
of PD-1/PD-L1 interaction was described by Bristol-
Myers Squibb. The BMS inhibitors are derivatives of 
(2-methyl-3-biphenylyl)methanol. The capability to block 
the PD-1/PD-L1 complex formation was demonstrated in 
the HTRF assay in the original disclosure, but no further 
confirmatory data or structural information was provided 
to date. Among their most potent examples, BMS-8 and 
-202 inhibited the formation of the PD-1/PD-L1 complex 
with the IC50 values of 0.146 and 0.018 µM, respectively. 
Despite the fact that these compounds have poor drug-
like properties and as such are unlikely to become lead 
structures, they serve well as a proof of principle that 
targeting the PD-1/PD-L1 interaction surface is feasible 
not only with antibodies, but also with small molecules. 
Therefore we attempted their detailed characterization in 
this study. Most importantly, we wished to characterize the 
hot spots and key interactions at the surface of the target 
molecule to guide future rational design of more drug-like 
inhibitors.
We demonstrated that BMS compounds bind to PD-
L1 and not PD-1 and presented direct confirmation by 
NMR that in vitro BMS-8 and BMS-202 are capable of 
Figure 5: Conformational changes upon PD-L1 interaction with BMS-202. Overlay of apo-PD-L1 (orange; PDB 5C3T) and 
PD-L1 structures derived from PD-L1/PD-1 complex (gray; PDB 4ZQK) and PD-L1/BMS-202 complex (blue - chain A) demonstrates 
significant rearrangement of Tyr56 sidechain disposition upon BMS-202 binding compared to much less pronounced changes observed 
upon PD-1 binding (Note the T-stacking interaction of Tyr56 with the distal phenyl moiety of the inhibitor. Similar for BMS-8 containing 
structure (not shown). The rearrangement of Met115 sidechain is in turn more pronounced upon PD-1 binding compared to BMS-202 
binding. Chain B of the PD-L1/BMS-202 dimer (green). PD-1 (red).
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dissociating the PD-1/PD-L1 interaction at stoichiometric 
concentration, consistent with the estimated K
D
 of the 
PD-1/PD-L1 complex of 8 µM [29]. Quite unexpectedly, 
however, the compounds induced dimerization of hPD-L1 
in solution. 
The presented crystal structures provide explanation 
for the molecular mechanism of dimerization of PD-L1 and 
the mechanism of inhibition of PD-L1/PD-1 interaction. 
The PD-L1 homodimer distantly resembles that of PD-1/
PD-L1 (both proteins are characterized by similar IgG 
like fold [20] in that the two molecules of PD-L1 interact 
via their PD-1 binding surfaces). Nevertheless, overlay 
of the PD-L1 homodimer with the PD-1/PD-L1 dimer 
demonstrates that the second PD-L1 molecule within the 
homodimer does not fully corresponds to the orientation 
of PD-1 (Figure 4A). In the respective structures, both 
BMS-202 and BMS-8 are located at the center of the 
homodimer filling a deep hydrophobic pocket contributing 
multiple additional interactions between the monomers. 
The compounds interact with both PD-L1 molecules using 
hydrophobic surfaces physiologically involved in the 
PD-1/PD-L1 interaction. This provides the rationale for 
the activity of BMS compounds in dissociating the PD-1/
PD-L1 complex. Not only the inhibitor partially covers 
the PD-1 binding site in each PD-L1 molecule within the 
complex, but the interaction of the two monomers fully 
occludes the PD-1 binding surface thus preventing the 
interaction with PD-1. Furthermore, neither BMS-202 nor 
BMS-8 induce changes in the overall protein fold, so that 
the arrangement of PD-L1 backbone remains the same as 
in the apo-form and in the PD-1/PD-L1 complex (Figure 
4B). 
The most important finding of this study is in 
unambiguous definition of the druggable “hot spots” 
[30-32] at the surface of PD-L1 suitable for targeting 
with low-molecular weight inhibitors. Even though 
the atomic resolution structures of PD-L1 [19] [33] 
and recently its complex with PD-1 [20] have been 
published by others and our group providing directions 
for rational inhibitor design, the large, relatively flat 
interaction surface significantly complicated the task. 
Based on the analysis of the structure of the PD-1/PD-
L1 complex, we have recently proposed the three likely 
hot spots [20], but only the structures reported in this 
study allowed to confirm the suitability of those for the 
design of small molecule inhibitors and defined particular 
interactions (pharmacophore) which should be explored. 
Importantly, these “hot spots” can likely be targeted by 
the compounds that not necessarily induce dimerization. 
Our study redefines the previously proposed sites and 
allows pinpointing PD-L1 residues important for the 
inhibitor binding with higher accuracy. As shown by the 
present crystal structures, BMS-202 and BMS-8 each 
target two of the previously described hot spots, which 
now may be treated as a single continuous interaction 
area. This target space consists of Tyr56, Met115, Ile116, 
Ala121 and Tyr123 forming an extended groove ideal 
for accommodating hydrophobic moieties (Figure S6). 
Presented herein new composite binding cleft does not 
exclude possible use of the previously described single 
“hot spots”, thereby creating novel possibilities for further 
inhibitor design. 
Interestingly, the inhibitor binding induces a small, 
but significant rearrangement of the sidechains at the 
surface of PD-L1 (compared to the apo-structure), which 
is partly different to that induced by the PD-1 interaction. 
In the case of the PD-1/PD-L1 complex, Tyr56 of PD-L1 
is rotated and rearranged towards the PD-L1 core, while 
the Tyr56 sidechain ring in PD-L1/BMS-202 complex is 
considerably moved towards the inhibitor molecule thus 
creating a T-stacking interaction with the benzyl moiety 
of the latter (Figure 5). Similar rearrangement is observed 
upon BMS-8 binding. This dynamic adjustment in PD-
L1 upon inhibitor binding provides further guidance for 
the rational design of small-molecule binders to PD-L1. 
Additionally, less pronounced adjustments include Ala18, 
Thr20, Met115, Ser117 and Tyr123 residues in the close 
vicinity of the inhibitor. Even though the compound does 
not impose significant changes in the overall backbone 
arrangement, minor rearrangements are visible in residues 
distant to the inhibitor binding site including Pro24, 
Asp61, His69, Glu71, Tyr81 and Arg113. These changes, 
however, are most likely caused by the dimerization rather 
than the small-molecule binding. 
This study was performed using soluble distal 
extracellular IgG like domain of PD-L1 which served 
well to characterize protein surface accessible for targeting 
with small molecule inhibitors. At the cell surface, 
however, PD-L1 is constrained by being anchored at 
the lipid bilayer. Overlay of the structure of full length 
extracellular domain of PD-L1 containing both IgG like 
domains on BMS-202 induced dimer and docking such 
a complex at the lipid membrane demonstrates that 
dimerization is sterically feasible at the cell surface (same 
is true for BMS-8 containing dimer). This is owned to a 
long spacer between the membrane and a relatively rigid 
“core” of the extracellular domain of PD-L1, which linker 
allows enough flexibility for the core to form a dimer 
characterized by geometry observed in our structures 
(Figure S11A). 
The proteins used in this study were produced in 
bacteria and as such lack glycosylation. We therefore 
evaluated if mammalian glycosylation could preclude 
BMS compound induced PD-L1 dimerization. The known 
glycosylation sites on PD-L1 are shown in Figure S11B 
and clearly do not sterically interfere with BMS-202 
induced dimerization. This was expected since PD-L1 
employs the same surface for dimerization and interaction 
with PD-1. Any glycosylation preventing dimerization 
would also preclude PD-1 binding.
Differential scanning fluorimetry employed here to 
evaluate the BMS compound selectivity between PD-L1 
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and PD-L2 demonstrated that both BMS-8 and BMS-202 
are specific for PD-L1. No crystal structure of the human 
PD-L2 (hPD-L2) is available to date and only murine PD-
L2 (mPD-L2) extracellular domain was crystallized in 
an apo form (PDB 3BOV) and in the complex with the 
murine PD-1 (mPD-1; PDB 3BP5). To speculate on the 
likely determinants of BMS compound specificity, we 
created a homology model of hPD-L2 based on mPD-L2 
structures. Both proteins contain a tryptophan residue 
(Trp57 in hPD-L1 and Trp110 in mPD-L2) in the center of 
the PD-1 interacting surfaces. However, the sidechain of 
this residue in hPD-L1 is hidden inside hydrophobic core 
of the protein (does not contribute to the interaction with 
PD-1 or BMS-202), while the sidechain of corresponding 
tryptophan in mPD-L2 is exposed to the solvent in the apo 
structure and oriented towards the PD-1 core in mPD-1/
mPD-L2 complex. Since the amino acid sequence identity 
of extracellular domains of hPD-L2 and mPD-L2 is 
73% and both proteins contain tryptophan at equivalent 
position (Ala-Trp-Asp-Tyr sequence in both proteins), it 
is likely that the sidechain of Trp57 in hPD-L2 has the 
same conformation as the corresponding tryptophan in 
mPD-L2. The resulting different surface arrangement of 
hPD-L1 and hPD-L2 at the binding site would explain the 
specificity of BMS compounds for hPD-L1. 
In conclusion, the presented data documents 
structural determinants guiding the recognition of small 
molecule inhibitors of PD-1/PD-L1 interaction by PD-L1. 
The unambiguous definition of the molecular “hot spots” 
at the surface of PD-L1 provides solid basis for future 
development of immunomodulating small molecules 
against cancer.
MATERIALS AND METHODS
Expression and purification of recombinant PD-
L1, PD-L2 and PD-1
The gene encoding human PD-L1 (amino acids 
18-134) was cloned into the pET-21b, the gene encoding 
human PD-L2 (20-220) was cloned into pET28a and that 
of human PD-1 (33-150, Cys93 exchanged to serine) into 
pET-24d. Proteins were expressed in the E. coli BL21 
(DE3). Cells were cultured in LB at 37°C. The protein 
production was induced with 1 mM IPTG at OD600 of 1.0 
and the cells were cultured for additional 5h. For hPD-
1, after induction the temperature was lowered to 30°C. 
Proteins were expressed as inclusion bodies which were 
collected by centrifugation, washed twice with 50 mM 
Tris-HCl pH 8.0 containing 200 mM NaCl, 0.5% Triton 
X-100, 10 mM EDTA and 10 mM 2-mercaptoethanol 
and once more with the same buffer with no detergent. 
The inclusion bodies were stirred overnight in 50 mM 
Tris pH 8.0 containing 6M GuHCl, 200 mM NaCl and 10 
mM 2-mercaptoethanol. Solubilized fraction was clarified 
by high speed centrifugation. hPD-L1 and hPD-L2 were 
refolded by drop-wise dilution into 0.1 M Tris pH 8.0 
containing 1 M L-Arg hydrochloride, 0.25 mM oxidized 
glutathione and 0.25 mM reduced glutathione for hPD-L1 
and 0.1 M Tris pH 8.5 containing 1 M NDSB201, 0.2 
M NaCl, 5 mM cysteamine and 0.5 mM cystamine for 
hPD-L2. hPD-1 was refolded in similar manner in 0.1 M 
Tris pH 8.0 containing 0.4 M L-Arg hydrochloride, 2 mM 
EDTA, 5 mM cystamine and 0.5 mM cysteamine. After 
refolding, the proteins were dialyzed 3 times against 10 
mM Tris pH 8.0 containing 20 mM NaCl, and purified 
by size exclusion chromatography on Superdex 75 (GE 
Healthcare) in 10 mM Tris pH 8.0 containing 20 mM 
NaCl. The purity and protein folding were evaluated by 
SDS-PAGE and NMR, respectively.
Analytical size-exclusion chromatography
The oligomeric state of tested proteins was analyzed 
by size exclusion chromatography. Superdex 75 10/30 HR 
(GE Healthcare) was equilibrated with PBS pH 7.4 and 
calibrated using globular proteins of known molecular 
weight. Approximate molecular weight of apo-PD-L1 and 
PD-L1-small molecule complex (3:1 compound : protein 
molar ratio) were estimated using the calibration curve.
Differential scanning fluorimetry (DSF)
DSF analysis was performed according to Niesen 
and colleagues [26]. In brief PD-L1 and PD-L2 (both 
12.5 µM) were incubated alone, with BMS-202 or BMS-
8 (both at 37.5 µM) in the presence of SYPRO Orange 
Dye (Life Technologies). Constant temperature gradient of 
0.2°C/min was applied and changes in fluorescence were 
monitored using real time thermocycler (BioRad). Melting 
temperature (Tm) was estimated from the first derivative of 
fluorescence intensity as a function of temperature. 
NMR methods 
Uniform 15N labeling was obtained by expressing 
the protein in the M9 minimal medium containing 15NH
4
Cl 
as the sole nitrogen source. Unlabeled proteins were 
prepared as for crystallization. For NMR measurements 
the buffer was exchanged by gel filtration to PBS pH 7.4 
(PD-L1) or 25 mM sodium phosphate containing 100 mM 
NaCl pH 6.4 (PD-1). 10% (v/v) of D2O was added to the 
samples to provide lock signal. All spectra were recorded 
at 300K using a Bruker Avance 600 MHz spectrometer. 
Binding of the compounds was analyzed by titrating 
the 15N-labeled PD-L1 (0.3 mM) and recording the 1H-15N 
HMQC spectra prior and after addition of the compound.
The ability of tested compounds to dissociate PD-L1 
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/ PD-1 was evaluated using AIDA [25]. 15N-labeled PD-1 
(0.2 mM) was slightly overtitrated with unlabeled PD-
L1. Compound was aliquoted into the resulting mixture. 
During the experiment the 1H-15N signals were monitored 
by HMQC experiment.
Changes in the oligomeric state of PD-L1 in the 
presence of tested compounds were monitored by titration 
of unlabeled PD-L1 (0.3 mM) while recording 1H spectra 
prior and after addition of the compound. The approximate 
molecular weights of protein populations present in the 
sample were determined by analyzing the linewidth 
(relaxation time) of well separated NMR signals.
Crystallization of PD-L1 in complex with BMS-
202 and BMS-8
Purified PD-L1 in 10 mM Tris pH 8.0 containing 
20 mM NaCl was mixed with BMS-202 or BMS-8 at 
1:1 molar ratio. The complex was concentrated to 8 mg/
ml. Sitting drop vapor diffusion setup and commercially 
available buffer sets were used to screen for crystallization 
conditions. Initially obtained crystals were optimized 
according to art. Diffraction-quality crystals of PD-L1/
BMS-202 complex were obtained at room temperature 
from 0.01 M Tris pH 8.5 containing 0.30 M sodium 
chloride and 27% (w/v) PEG 4000 while those of PD-L1/
BMS-8 complex from 0.2 M ammonium formate and 20% 
(w/v) PEG 3350.
Structure determination and refinement
Crystals were flash-cooled in liquid nitrogen 
without additional cryoprotection. The diffraction data 
was collected at the Helmholtz Centrum 14.1 beamline 
at BESSY (Berlin, Germany) [34]. The data were 
indexed and integrated using XDS [35-36] and scaled 
and merged using Scala [37]. Molecular replacement 
was calculated using Phaser [38]. The structure of the 
recently solved human PD-L1 (PDB 5C3T) was used as 
a probe [20]. The protein models were manually built 
in the resulting electron density maps using Coot [39]. 
Restrained refinement was performed using Phenix [40] 
and Refmac 5.0 [41]. Five percent of the reflections were 
used for cross-validation analysis. The behavior of Rfree 
was employed to monitor the refinement strategy. Inhibitor 
model and restraints were prepared in eLBOW [42] and 
introduced into the model at advanced stage of refinement 
when electron density describing the ligand was clearly 
visible. Water molecules were added using Coot and 
manually inspected. Molecular graphics was prepared with 
PyMOL (http://www.pymol.org/). 




biphenyl]-3-yl)methoxy)benzaldehyde and the final 
compounds were prepared according to procedures 
described in BMS patent [18] with minor modifications 
(Figure S12). All reagents were obtained from Sigma 
Aldrich and used without additional purification. NMR 
spectra were recorded on Bruker Avance 300 or 600 MHz 
spectrometers (Figures S13-S16). All chemical shifts (δ) 
are reported in ppm and coupling constants (J) in Hz. The 
identity and purity of all compounds was additionally 
analyzed by high-resolution mass spectrometry (HRMS) 
and HPLC. 
Accession codes
Coordinates and structure factors were deposited 
in the Protein Data Bank with accession numbers 5J89 
(BMS-202) and 5J8O (BMS-8).
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